Drug intelligence / Profile preview

hydroxychloroquine + letrozole + palbociclib

Development stage: Unknown
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Small Molecules
Administration: Oral

Overview

This is a combination therapy under investigation for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Hydroxychloroquine is an autophagy inhibitor, letrozole is an aromatase inhibitor that reduces estrogen production, and palbociclib is a CDK4/6 inhibitor that blocks cell cycle progression. The combination aims to enhance the efficacy of endocrine therapy and overcome resistance by inhibiting autophagy induced by low-dose palbociclib[1][2][5].

Other names: HCQ + letrozole + palbociclibhydroxychloroquine/letrozole/palbociclib

Targets

CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on hydroxychloroquine + letrozole + palbociclib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydroxychloroquine + letrozole + palbociclib.

Explore the full profile